Neurocrine's CRENESSITY Shows Long-Term Growth Benefits in Pediatric CAH Patients

Event summary

  • Neurocrine Biosciences presented two-year data from the Phase 3 CAHtalyst Pediatric study at ENDO 2026, showing slowed bone age progression and improved predicted adult height in pediatric CAH patients treated with CRENESSITY.
  • Among patients with advanced bone age at baseline, mean bone age SDS decreased by 1.12, with some patients showing reductions greater than two standard deviations.
  • Caregiver survey data showed universal satisfaction with CRENESSITY, with 100% of respondents reporting likelihood to recommend the treatment.
  • CRENESSITY was generally well tolerated through two years of treatment, with no new safety signals observed.

The big picture

Neurocrine's data suggests CRENESSITY could address a critical unmet need in pediatric CAH management by slowing abnormal bone maturation. The results position the drug as a potential differentiator in a market historically reliant on glucocorticoid treatments with significant side effects. The company's ability to demonstrate sustained benefits could drive broader adoption and support its growing portfolio in rare endocrine disorders.

What we're watching

Long-Term Efficacy
Whether the observed improvements in bone age progression and predicted adult height will be sustained beyond two years of treatment.
Market Adoption
The pace at which CRENESSITY gains acceptance among physicians and caregivers for pediatric CAH patients.
Regulatory Landscape
How the FDA and other regulatory bodies may respond to long-term data, potentially impacting future approvals or labeling.